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Conclusion: Salvage EBRT after SIRT was effective for HCC 
patients with PVT. The 3D dose summation and BED-DVH of 
combined therapy help to predict liver toxicity. By carefully 
selecting patients, the combined therapy bring acceptable 
toxicities incidence.  
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Purpose or Objective: Unflattened surface HDR 
Brachytherapy applicators commonly suffer from dose fall off 
on the side of the dose distribution. Recent research 
documented that in addition to missing dose at the side of 
the applicator vertical type HDR Brachytherapy surface 
applicators are subject to underdose in the middle of the 
treatment region. This artifact is clinically relevant because 
tumor cells in the middle of the treated area can end up 
irradiated insufficiently. In this work we present a surface-
dose compensation body generated with a 3D printer that 
specifically addresses the dose irregularities of a vertical 
type HDR Brachytherapy surface applicator. In order to 
overcome the limitation of increased treatment time of 
applicator flattening for horizontal type applicators we 
utilize the possibility of using a source position nearer to the 
surface to generate a flattened dose distribution together 
with reduced treatment time. 
 
Material and Methods: A 40 mm Varian VariSource 
GM11010080 applicator was used for the modification (Varian 
Medical Systems, Inc., Palo Alto, CA, USA). The source 
position is 1.5 cm from applicator tip. The depth of 
evaluation is 0.5 cm solid water material. A consumer grade 
3D printer “UP! 3D, Beijing TierTime Technology Co. Ltd.” 
was used to print out a negative form with ABS plastic. 
Lippowitz type low temperature melting metal was used to 
mold the positive form of the flattening elements. All dose 
measurements and flatness evaluations were performed with 
Gafchromic EBT3 film Lot #: 12021402 and the FilmQA 
software, flatness and symmetry toolbox (both Ashland 
Speciality Ingredients, Bridgewate, NJ, USA). 
 
Results: The generated compensation element is of toroidal 
shape, for the standard source position 1.5 cm from appliator 
tip, has a maximum thickness of 1.5 mm in surface direction. 
The output of the applicator with flattening element 
occurred to be 75% of the unflattened one. The diameter of 
80% nominal dose area increased from 35.2 mm with the 
unflattended applicator to 50.2 mm with the flattening 
element in place. The asymetric central low-dose artefact 
can be compensated to a clinical acceptable minimum dose. 
When utilizing the source position 1 cm from tip a prototype 
filter could bring the width of the 80% dose area to 45.0 mm, 
above the nominal applicator size, and output to 112 % of an 
unflattened applicator. The position 0.5 cm from tip is still 
considered flattable with increased low dose area in out of 
field tissue due to applicator geometry when quick treatment 
is of clinical interest. The first soure position on applicator 
tip is not flattable for clinical use. 
 
Conclusion: The presented prototype of a dose compensation 
body can remove the dose artefacts of a vertical type HDR 
Brachytherapy surface applicator including the clinical 
relevant underdosed central region. With the appropriate 
flattening body it is now possible to utilize a source position 
nearer to surface and compensate for dose output loss when 
using a dose flattening element. 
 
EP-2021  
Cosmesis and acute toxicity outcomes in skin lesions 
treated with High-Dose-Rate Brachytherapy. 
H. Pérez-Montero
1Hospital 12 de Octubre, Radiation Oncology, Madrid, Spain 
1, A. Campos1, M.P. Crespo1, B. Gil1, A.M. 
Cabezas1, T.C. Chávez1, V. Rodríguez1, N. Gascón1, J.F. 
Pérez-Regadera1 
 
Purpose or Objective: Skin cancer is the most common 
malignancy in white population. The most prevalent 
histologies are basal cell carcinoma (BCC) followed by 
squamous cell carcinoma (SCC). They are locally aggressive 
lesions that rarely metastasize and their prognosis depends 
on local control. Due to their localization and superficial 
nature, cosmetic result of the treatment is of primary 
importance. High-Dose-Rate brachytherapy (HDR-BT) is a safe 
and effective treatment option for these carcinomas and for 
other skin lesions. There are two main techniques for its 
delivery: interstitial brachytherapy and plesiotherapy.  
We have evaluated early local control, acute toxicity and 
cosmetic outcomes in all patients treated with HDR-BT in our 
center. 
 
Material and Methods: We assessed 47 patients who had 52 
skin lesions. There were 29 SCCs, 14 BCCs, 4 keloid scars, 3 
adenocarcinomas,1 lentigo maligna and 1 Merkel cell 
carcinoma. Median age of treated patients was 78 years (34-
93). Data was collected prospectively.All lesions were 
treated with HDR-BT at our institution between December 
2014 and August 2015 by interstitial brachytherapy or 
plesiotherapy. Average total dose delivered was 35,63 Gy and 
Median dose delivered was 40,5 Gy.  
Acute toxicity was graded using the Common Terminology 
Criteria for Adverse Events, version 4.0 and cosmetic 
outcomes were classified using the Radiation Therapy 
Oncology Group cosmetic rating scale. 
 
Results: Average follow-up from completion of treatment 
was 5.5 months (2-10.1). The overall crude recurrence rate 
was 3,8% (n = 2). Grade 0 acute toxicity was observed in 7.7% 
of treated lesions (n = 4), grade 1 in 63.5% (n = 33), grade 2 
in 21.2% (n = 11) and grade 3 in 7.7% (n = 4). No acute 
toxicity greater than grade 3 was observed. All acute toxic 
events were resolved between the first and the second month 
after brachytherapy. Cosmetic results were excellent or good 
in 92.3% of the cases (n = 48), fair in 3.8% (n = 2) and not 
evaluable in 2 patients whose tumours were not cured. 
 
 
ESTRO 35 2016                                                                                                                                                    S955 
________________________________________________________________________________ 
Conclusion: HDR-BT seems to be a good alternative for 
treatment of epitheliomas in special locations, above all in 
elderly patients with comorbidities that preclude surgery. Its 
ability to treat a wide area with minimal alteration of normal 
tissues allows a high probability of cure with excellent 
cosmetic results and without affecting functionality.  
We can conclude that HDR-BT could be a valid alternative to 
surgery with acceptable acute toxicity, good early local 
control and exceptional cosmetic outcomes in skin lesions. 
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Purpose or Objective: Rhabdomyosarcoma of the vagina is 
very rare disease, mainly girls were 1-3 years, only a few 
patients were 13-15 years old. Early studies have shown the 
advantage of intracavitary radiation therapy over surgical 
treatment and EBRT. There are new methods of planning 
EBRT from CRT moved to VMAT and IMRT. The emergence of 
new techniques in the EBRT and brachytherapy inspired us to 
the evaluation of methods of treatment children's vaginal 
rhabdomyosarcoma. 
 
Material and Methods: From 1980 till 2015 38 patients 
received intracavitary brachytherapy with source Co-60 and 
Ir-192. In our cancer center were made special applicators of 
different designs. The main treatments were applicators for 
direct 8 mm diameter and a length of about 6-7 cm. Were 
specially made Co-60 tube source (LDR). Children were 
immobilized for several days. The active length was 4-5 cm.  
Since the 90s we switched to using stepping source Ir-192 
HDR. Normalisation point changed from 5 mm to 2 mm from 
the surface of applicator.This made it possible to irradiate 
the entire vagina. 
Planning is optimized for the creation of uniform dose 
distribution throughout the vagina. Accordingly, it was 
necessary to calculate dose distribution for these cases. For 
calculations were chosen CT and MRI and patient anatomy 
was extended, contoured target and OAR's. The calculation of 
CRT / IMRT / VMAT / Brachy. CTV was 6.5 cm3. 
Unlike cervical cancer, in OAR's we added the urethra, which 
is located close to vagina, and which dose close to 100%. We 
have calculated % dose to the rectum, bladder, urethra and 
ovaries. For EBRT, we calculated the mean dose to OAR's, 
Brachytherapy for rectum and bladder, we calculated dose to 
1 cm3, and the entire volume of urethra and ovaries. 
 
Results: In both cases (EBRT and Brachy) ovaries was about 
2% (2.0% -2.3%) of normalisation dose. However, it is worth 
considering that brachytherapy is given high dose per 
fraction, so radiobiological dose above.  
CRT / IMRT / VMAT / Brachy:  
Rectum: 37.7 / 26.6 / 29.9 / 37.2 % 
Bladder: 58.7 / 39.6 / 37.1 / 30.8 % 
Uretra: 99.0 / 99.2 / 97.2 / 50.2 % 
 
Conclusion: Although improvement in EBRT (from CRT to 
IMRT and VMAT) and decrease in dose to OAR's, 
brachytherapy maintains its position in the treatment of this 
localization. When less integral dose brachytherapy and dose 
on OAR's (not whole body is irradiated, but only part of it), 
which significantly reduces late effects. In modern time, we 
should pay attention to other radionuclides, which can give 
uniform dose distribution (example Yb-169). 
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Purpose or Objective: To characterize PD-L1 expression in 
non-small-cell lung cancer (NSCLC) cell lines, and explore the 
relationship between immunology escaping and tumor cell 
proliferlation and apoptosis with receiving radiotherapy. 
 
Material and Methods: Evaluating the PD-L1 protein and 
CD8+ T cells with immunohistochemistry in tumor tissue from 
NSCLC patients. In vitro assay, to detect the expression of 
PD-L1 in different NSCLC cell lines after conventional and 
hypofractionated radiation therapy by westernbloting and 
study the difference between A549 and radiation resistance 
A549 cell line by flow cytometry and westernbloting. To 
analysis PI3K/Akt and stat3 proliferation pathway and Bcl2 
family apoptosis signaling pathway in A549 radiation 
resistance cell by westernbloting. Small interfering RNA 
(siRNA) was used to A549 radiation resistance cell, and then 
to observe the difference in PI3K/Akt and stat3 pathway. As 
for in vivo study, immunohistochemistry was used to detect 
the relationship between the expression of PD-L1 and NF-KB 
protein in control group, anti-PD-L1 group, radiation group 
and radiation plus anti-PD-L1 group. 
 
Results: We found that patients whose tumor expression the 
higher PD-L1 protein, who had the more radiation resistance 
and had less CD8+ T cell around tumor microenvironment. 
PD-L1 protein improved obviously in NSCLC cell lines after 
receiving conventional radiation, but there is not the same 
tendency after hypofractionated radiation. We found that 
A549 radiation resistance cell had activation in PI3K/Akt and 
stat3 pathway and its’ NF-KB protein would be up-regulation. 
When the A549 acquired radiation resistance, it would be 
apoptotic less. We observed the activation of the anti-
apoptosis protein bcl2 and the inhibition of the pro-apoptosis 
protein bim in A549 radiation resistance cell. After siRNA 
interfering to this cell, it’s PD-L1 protein decreased. A549 
radiation resistance cell came to be apoptosic. While it’s 
pAkt, pstat3 and NF-KB didn’t change. 
 
Conclusion: Conventional radiation would be easy to induce 
radiation resistance by overexpressing the PD-L1. When the 
lung cancer cell express PD-L1 more, the tumor would escape 
from CD8+ T cell. NF-KB protein is the key to up-regulation 
PD-L1. When PD-L1 overexpression, lung cancer would be 
apoptosis less and immunity escaping. SiRNA interfering PD-
L1 can eliminate the radiation resistance of the A549 cell 
line. It provide the evidence for the combination of the anti-
PD-L1 drug and radiation therapy in clinic. 
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